As DexCom Inc. CEO Terrance Gregg sees it, smartphone apps will be central to future diabetes management, and his firm plans to be at the forefront.
The continuous glucose monitoring firm has one of the few mobile-app-centric, high-risk, class III device submissions under FDA review right now with its Share platform, which provides a mechanism to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?